Steroid-Based Therapy and Risk of Infectious Complications
PLoS Med 2016 May 24; 13:e1002024
Lionel Rostaing, Paolo Malvezzi
Clinique Universitaire de Néphrologie, Unité de Transplantation Rénale, CHU Grenoble, La Tronche, France
Université Toulouse III Paul Sabatier, Toulouse, France
INSERM U563, IFR–BMT, CHU Purpan, Toulouse, France
Steroid-based therapy is widely used in the treatment of different diseases, across many health care settings. In a study based on the National Health and Nutrition Examination Survey (NHANES), conducted between 1999 and 2005, the prevalence of long-duration glucocorticoid use in the United States general population was 1.2% (95% CI 1.1–1.4) .
In a study of the United Kingdom general population, over 20 years, the long-term use of glucocorticoids (>3 months) was 0.75% (95% CI 0.74–0.75) .
Over this time period, long-term corticosteroid prescriptions for rheumatoid arthritis, polymyalgia rheumatica/giant cell arteritis, ulcerative colitis, asthma, chronic obstructive pulmonary disease (COPD), and Crohn’s disease were evident.
In addition, among patients with a solid-organ transplant, who number more than 1 million worldwide, at least 50% take 5–10 mg of glucocorticoids per day over the long term.
With this in mind, it is of utmost importance that patients are managed in the best way with regards to side effects, particularly infectious complications…..